Navigation Links
Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
Date:5/20/2008

ist(TM) should

be used with caution in patients with cardiovascular disorders,

especially coronary insufficiency, cardiac arrythmias, and

hypertension.

Funding for these studies was provided by Dey, L.P., manufacturer and marketer of Perforomist(TM) (formoterol fumarate) Inhalation Solution. Perforomist(TM) Inhalation Solution is the first and only FDA-approved nebulized form of formoterol fumarate. Formoterol fumarate is a rapid and long-acting beta(2)-agonist (LABA) that has been previously available in the U.S. in a dry powder formulation with twenty years of worldwide experience. Nebulizers convert liquid medication into a mist that patients inhale through a mouthpiece or facemask.

"Taken together, these studies expand our understanding of the clinical benefits of Perforomist(TM) Inhalation Solution for the treatment of COPD," said Carolyn Myers, Ph.D., President of Dey, L.P. "Perforomist Inhalation Solution offers physicians a flexible, safe, and highly effective treatment option for COPD -- and many patients may benefit from this new addition to the treatment armamentarium."

About Perforomist(TM) Inhalation Solution

Indication

Perforomist(TM) Inhalation Solution is indicated for the long-term, twice-daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema.

Important Safety Information

Perforomist(TM) Inhalation Solution belongs to a class of medications known as long-acting beta(2)-adrenergic agonists (LABAs). LABAs may increase the risk of asthma-related death. Data from a large placebo-controlled US study comparing the safety of another LABA (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a LABA), the active
'/>"/>

SOURCE Dey, L.P.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
2. Clinical Trial Data on the Safety and Efficacy of Concomitant Formoterol Fumarate/ Tiotropium Treatment for COPD
3. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
4. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
5. Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination
6. Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
7. Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
8. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
9. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
10. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
11. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
(Date:1/15/2014)... Jan. 15, 2014  In an unprecedented effort to curb the spread ... and other transport vehicles, an advanced and portable UV germicidal lamp ... the first time. In order to prevent EMS ... pathogens, West Palm Beach Fire Rescue is ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... FRANCISCO, Calif., June 01, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, ... from ongoing clinical,studies of SNS-595 and SNS-032 at ... being held June 7-10, 2007 in Vienna,Austria. , ... Phase 1 clinical trial of SNS-595 in acute ...
... Zurich, June 1, 2007-Cytos Biotechnology AG is ... presentations of its novel,immunotherapeutic CYT003-QbG10 to treat ... were obtained,and will be presented in different ... Academy of Allergology and Clinical Immunology,(EAACI), taking ...
Cached Medicine Technology:Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 2Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 3CYT003-QbG10 to treat allergy to be presented at the Congress of,the European Academy of Allergology and Clinical Immunology,(EAACI), June 9-13, 2007 2
(Date:4/23/2014)... Physical Activity on Mobility Limitation in Old Age , ... of mobility limitation in old age, whereas leisure-time physical ... study which followed up 5,200 public sector employees for ... Research Center in Finland and the Finnish Institute of ... wears the body and lasts for several hours a ...
(Date:4/23/2014)... have shown that proliferation of endogenous neural precursor ... neurons and axons. From the perspective of neural ... Yat-sen University in China observed the effects of ... cell proliferation and expression of basic fibroblast growth ... brain on the infarct side. The researchers found ...
(Date:4/22/2014)... Government and industry leaders visited the New Jersey ... President Joel S. Bloom for the launch of ... corporation that provides a new model for business ... higher education assets and investment. U.S. Senator Cory ... CEO Joe Taylor, New Jersey Lieutenant Governor Kim ...
(Date:4/22/2014)... provide primary care for low-income patients may ease ... companies while improving patient health, researchers have concluded. ... health clinics that avoid costs associated with insurance ... hospital admission rates and emergency room visits, according ... Altoona. , The researchers estimated that the ...
(Date:4/22/2014)... of pregnancy among women using a newer method of ... times greater over a 10-year period than using the ... at Yale University and UC Davis has found. ... Contraception , the study found the higher risk of ... brand name Essure. , "This study provides essential ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... April 6 (HealthDay News) -- Compared with normal weight ... and infections during and after a hysterectomy, a new ... 20,353 women who had a hysterectomy to treat non-cancerous ... tumors and pain. Women with a body-mass index ...
... able to predict which adults with mild cognitive impairment are ... results of a study published online and in the June ... is an intermediate stage between the decline in mental abilities ... associated with dementia, a group of brain disorders that includes ...
... national prescribing patterns shows that more than half of ... filled another opioid prescription within the previous 30 days. ... at reducing abuse of prescription opioids. Researchers from ... of the National Institutes of Health, will publish results ...
... , TUESDAY, April 5 (HealthDay News) -- For people ... promise, researchers report. The device, surgically placed just ... jolt to the carotid arteries. This is said to ... activation therapy. The researchers were scheduled to present ...
... persistence and recurrence of H5N1 avian influenza in endemic regions ... birds. Trade in poultry, poultry products and caged birds, and ... these areas. Several recent outbreaks of avian influenza have suggested ... the virus over long distances. In a paper ...
... April 5 (HealthDay News) -- The substantial increase in ... emergency departments between 1995 and 2008 highlights the need ... researchers. They analyzed National Hospital Ambulatory Medical Care ... rose from about 330,000 in 1995 to 1.65 million ...
Cached Medicine News:Health News:Weight Linked to Complications in Some Hysterectomy Patients 2Health News:Using MRI, researchers may predict which adults will develop Alzheimer's 2Health News:Analysis of opioid prescription practices finds areas of concern 2Health News:Implantable Device May Lower Tough-to-Treat Hypertension 2Health News:Implantable Device May Lower Tough-to-Treat Hypertension 3Health News:Migratory birds, domestic poultry and avian influenza 2Health News:Migratory birds, domestic poultry and avian influenza 3Health News:As CT Scans of Kids Soar, Experts Urge Oversight 2
The Accuref 8001 allows you to measure much smaller pupils than conventional units and 3 step Target light adjuster ensures accurate results....
Sterile perfluorocarbon for intraocular Application....
Alcon offers medical grade perfluoropropane (SF6) intraocular gases for ophthalmological use....
Round knurled handle. Overall length 130 mm....
Medicine Products: